Our products focus on a complete and systematic degradation of gluten immunogenic peptides
Discovery – Lead Optimization – Manufacturing – Pre-Clinical – Clinical
Currently undergoing Discovery
Solution for non-celiac gluten sensitivity
AMY01 is a specific combination of exopeptidases, which destroys the immunogenic potential of GIPs. It is being developed as a dietary supplement to alleviate symptoms in people suffering from non-celiac gluten sensitivity. Although 6-10% of human beings suffer from non-celiac gluten sensitivity, no effective diagnostic test for the pathology exists. However, the ever growing awareness around celiac disease and gluten related disorders has led a large portion of individuals affected by non-celiac gluten sensitivity to look for solutions.
Whilst a range of existing products claim to be helpful in the digestion of gluten, a strict gluten-free diet is the only effective treatment for non-celiac gluten sensitivity to date. So far, several approaches have failed to target and effectively treat the underlying cause of non-celiac gluten sensitivity and celiac disease, namely gluten immunogenic peptides (GIPs), which derive from incomplete digestion of gluten and trigger inflammatory immune responses.
AMY01 is currently undergoing a GRAS notice application in the US and will soon undergo the novel food application in Europe. We intend to partner the dietary supplement with a global consumer health company for marketing, sales and distribution. This will soon give people affected by non-celiac gluten sensitivity access to our product.
Solution for celiac disease
A novel diagnostic test for non-celiac gluten sensitivity
AMYRA is currently cooperating with leading institutions in the field of molecular immune diagnostics to develop an immunological test for the differentiation between celiac disease and non-celiac gluten sensitivity. Whilst celiac disease can be diagnosed via a three step process involving blood tests, bowl biopsies and a patient’s responses to a gluten free diet, no serological biomarkers have been identified for the diagnosis of non-celiac gluten sensitivity. An effective diagnostic test is therefore an important step towards accurate verifications of and distinctions between non-celiac gluten sensitivity and celiac disease as well as expanding the market for AMY01, our dietary supplement.